Hospitals | May 23, 2026
Fortis Healthcare FY26 revenue crosses Rs. 9,100 crore
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
Q4 FY26 PAT jumps 44% to Rs. 271 crore, supported by acquisitions, specialty expansion, and diagnostics momentum
The trial will assess Precem-TcT, both as monotherapy and in combination with bevacizumab, in patients whose disease has progressed after or become resistant to standard treatments
Clears major obesity endpoints at 80 weeks
The approval was granted by Agenzia Italiana del Farmaco
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Organizations that embrace it thoughtfully today will help shape a healthier tomorrow, for India and beyond
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Pfizer says the broader dataset across all 25 serotypes strengthens confidence that the program can meet non-inferiority thresholds in its upcoming Phase 3 pediatric trials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
